ACTRN12620000662965已完成2 期
Reboxetine and combination therapy with AD128 in sleep apnoea trial: A double-blind, 3-way cross-over study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 16
研究概览
简要总结
A single 4mg dose of reboxetine modestly reduces obstructive sleep apnea (OSA) severity without further improvement with the addition of an antimuscarinic. These findings provide insight into the role of norepinephrine reuptake inhibitors on upper airway stability during sleep and are important for pharmacotherapy development for OSA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Otherwise healthy men and women with obstructive sleep apnoea aged 18-65 years
- •BMI between 18.5 and 40.0 kg/m2, inclusive, at visit 1.
排除标准
- •-Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
- •Medical Conditions
- •1.History of narcolepsy.
- •2.Clinically significant craniofacial malformation.
- •3.Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or poorly controlled hypertension.
- •4.Clinically significant neurological disorder, including epilepsy/convulsions.
- •5.History of schizophrenia, schizoaffective disorder or bipolar disorder according to Diagnostic and Statistical Manual of Mental Disorders-V (DSM V) or International Classification of Disease tenth edition criteria.
- •6.History of attempted suicide or suicidal ideation within 1 year prior to screening, or current suicidal ideation.
- •7.History of clinically significant constipation, gastric retention, or urinary retention, benign prostatic hyperplasia.
- •8.History of moderate or severe hepatic or renal impairment.
- •9.History of drug abuse or substance use disorder as defined in DSM-V within 12 months.
- •10.A significant acute illness or infection requiring medical treatment in the past 30 days.
- •11.Clinically significant cognitive dysfunction.
- •12.Narrow angle glaucoma.
- •13.Women who are pregnant or nursing.
- •14.Allergy to the study medications
- •15.Any medication known to influence breathing, sleep/arousal or muscle physiology.
- •16.Claustrophobia.
- •17.Use of medications from the list of disallowed concomitant medications.
- •18.Treatment with strong cytochrome P450 3A4 (CYP3A4) inhibitors, strong cytochrome P450 2D6 (CYP2D6) inhibitors, or monoamine oxidase inhibitors (MAOI) within 14 days of the start of study.
- •Prior/Concurrent Clinical Study Experience
- •19.Use of another investigational agent within 30 days or 5 half-lives, whichever is longer, prior to dosing.
- •Other Exclusions
- •20.<5 hours typical sleep duration.
- •21.Night- or shift-work sleep schedule.
- •22.Employment as a commercial driver or operator of heavy or hazardous equipment.
- •23.Smoking more than 10 cigarettes or 2 cigars per day.
- •24.Unwilling to use contraception during the study (if relevant).
- •25.Unwilling to avoid alcohol on the days of the study.
- •26.Unwilling to limit caffeinated beverage intake (e.g., coffee, cola, tea) to 400 mg/day or less of caffeine, not to be used within 3 hours of bedtime on study days.
- •27.Any condition that in the investigator’s opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.
- •28.Participant considered by the investigator, for any reason, an unsuitable candidate to receive the study medications or unable or unlikely to understand or comply with the study design.
研究者
相似试验
已完成
2 期
Effect of AD128 to Treat Obstructive Sleep ApneaSleep Apnea, ObstructiveNCT04394143Raphael Heinzer15
招募中
2 期
Reboxetine for Sleep Apnoea After ENT SurgerySleep Apnea, ObstructiveNCT05978505Flinders University20
招募中
1 期
Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin TherapyObstructive Sleep ApneaNCT05550246Brigham and Women's Hospital22
已完成
1 期
Atomoxetine and Oxybutynin in Obstructive Sleep ApneaObstructive Sleep Apnea (OSA)NCT02908529Brigham and Women's Hospital22
招募中
1 期
Atomoxetine and DAW2022 on OSA SeverityObstructive Sleep ApneaNCT05350215Brigham and Women's Hospital18